Acrivon Therapeutics(ACRV) - 2024 Q2 - Quarterly Results

Acrivon Therapeutics Reports Second Quarter 2024 Financial Results and Business Highlights WATERTOWN, Massachusetts, August 13, 2024 – Acrivon Therapeutics, Inc. ("Acrivon" or "Acrivon Therapeutics") (Nasdaq: ACRV), a clinical stage precision medicine company utilizing its Acrivon Precision Predictive Proteomics (AP3) platform for the discovery, design, and development of drug candidates through a mechanistic match to patients whose disease is predicted sensitive to the specific treatment, today reported fi ...